GOSS — Gossamer Bio Cashflow Statement
0.000.00%
- $86.46m
- $148.04m
- $48.47m
Annual cashflow statement for Gossamer Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -234 | -229 | -180 | -56.5 | -170 |
| Depreciation | |||||
| Non-Cash Items | 42.6 | 45 | 33.9 | 12.8 | 12.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.774 | -4.46 | -14.8 | 39.5 | -13.6 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -189 | -187 | -159 | -3.47 | -171 |
| Capital Expenditures | -1.55 | -0.41 | 0 | 0 | -0.079 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -116 | -0.625 | -111 | 29 | 156 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -117 | -1.03 | -111 | 29 | 156 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.33 | 117 | 190 | -11.5 | 6.42 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -303 | -71.5 | -79.9 | 14 | -8.34 |